Abstract 1570P
Background
New breast cancer (BC) cases in county regions, including rural areas, account for 33% of all BC cases annually in China. Women residing in county areas generally have lower economic income and educational levels compared to urban women, lacking the access to medical resources. We utilized real-world data to explore the factors and impacts of delayed presentation for BC patients (pts) in county areas.
Methods
CHASE001 (NCT05544123) was an observational, multicenter study assessing real-world treatment patterns among BC pts in county areas of China. Descriptive statistics reported patient intervals and demographics. Multivariate regression analyses (MVA) and rank-sum test were used to analyze factors and impacts associated with delayed presentation.
Results
This analysis included 2405 BC pts with pathological diagnosis from February 2001 to July 2023. The median time from symptom onset to the first presentation to a healthcare professional was 1.0 month (IQR 0.3-5.0). the proportion of delayed presentation (intervals≥3 months) was 28.4%. The median interval among pts with delayed presentation was 12.0 months (IQR 6.0, 24.0). MVA revealed that lower education levels (OR 1.37 [95% CI 1.13-1.67]; p=.002), lack of breast screening (OR 1.42 [95% CI 1.06-1.91]; p=.019), being farmers and unemployed (OR 1.36 [95% CI 1.01-1.83]; p=.045), and residing in county areas in western China (OR 1.71 [95% CI 1.38-2.12]; p<.001) were significantly associated with delayed presentation. The rank-sum test demonstrated that delayed presentation was linked with higher disease burden. The proportion of pts with delayed presentation diagnosed with stage III-IV (p<.001), tumor size≥2cm (p<.001), and more than three positive lymph nodes (p=.005) was significantly higher than those who sought timely care.
Conclusions
This analysis indicates that patient delays are influenced by social determinants of health. Lower socioeconomic status and education levels are risk factors for delayed presentation, and medical resources are unevenly distributed across regions. Therefore, promoting early presentation through advocacy, education, and policy should be prioritized, especially targeting socially deprived and less educated populations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10